RT Journal Article
T1 Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation
A1 Lens, Sabela
A1 García Eliz, María
A1 Fernández Vázquez, María Inmaculada
A1 Castells, Lluis
A1 Bonacci, Martin
A1 Mas, Antoni
A1 Crespo, Gonzalo
A1 Buti, María
A1 Prieto, Martín
A1 Forns, Xavier
AB Background & Aims: The combination of hepatitis B immunoglobulin and a nucleos(t)ide analogues has markedly reduced the rate of hepatitis B virus recurrence afterliver transplantation; however, the optimal duration of hepatitis B immunoglobulin has not been clarified. This lack of consensus perpetuates the use of different strategies.The aim of this study was to evaluate the risk factors associated to hepatitis B virus recurrence after liver transplantation in a large cohort of patients under differenthepatitis B immunoglobulin regimens.Methods: Retrospective multicentre analysis of hepatitis B virus-related liver transplantation recipients receiving combined prophylaxis (hepatitis B immunoglobulin + nucleos(t)ide analogues). The strategy of short-term hepatitis B immunoglobulin was compared to lifelong administration. Hepatitis B virus recurrence was defined as positive HBsAg after liver transplantation.Results: Three hundred and thirty-eight patients were analysed. After a median follow-up period of 72 months, 37 patients (11%) developed hepatitis B virus recurrence. Hepatocellular carcinoma recurrence and lamivudine resistance after liver transplantation were the only factors independently associated to hepatitis B virus recurrence (HR 5.4 [2.3-12] and 9.3 [4.2-20] respectively P < .001). HBsAg reappearance after hepatitis B virus recurrence was transient (16 patients), persistent (15) or alternant (6). The hepatitis B immunoglobulin regimen did not have an impact on therate or evolution of hepatitis B virus recurrence. Overall, patient survival was good and not influenced by hepatitis B virus recurrence (82% at 5 years). Fulminant liverfailure, hepatitis C coinfection or hepatocellular carcinoma at liver transplantation were independent risk factors for lower survival.Conclusions: Liver transplantation is an effective treatment for hepatitis B virus-related liver disease. Since the introduction of combined prophylaxis the rate of hepatitisB virus recurrence is very low. However, lifelong hepatitis B immunoglobulin administration does not seem necessary to reduce hepatitis B virus recurrence.
PB WILEY
SN 1478-3223
YR 2018
FD 2018-04-01
LK https://hdl.handle.net/20.500.14352/126162
UL https://hdl.handle.net/20.500.14352/126162
LA eng
NO Lens S, García-Eliz M, Fernández I, Castells LL, Bonacci M, Mas A, Crespo G, Buti M, Prieto M, Forns X. Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver Int. 2018 Abr;38 (11):1940–1950.
NO Fondos FEDER
NO Instituto de Salud Carlos III (España)
DS Docta Complutense
RD 8 jun 2026